BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

812 related articles for article (PubMed ID: 31865731)

  • 21. Adjuvant radiotherapy for stage pN1M0 esophageal squamous cell carcinoma: Results from a Chinese two-center study.
    Ni W; Chen J; Xiao Z; Yu S; Zhang W; Zhou Z; Chen D; Feng Q; Chen X; Lin Y; Zhu K; Gao S; Xue Q; Mao Y; Cheng G; Sun K; Liu X; Fang D
    Thorac Cancer; 2019 Jun; 10(6):1431-1440. PubMed ID: 31102336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
    Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
    Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
    Tang H; Wang H; Fang Y; Zhu JY; Yin J; Shen YX; Zeng ZC; Jiang DX; Hou YY; Du M; Lian CH; Zhao Q; Jiang HJ; Gong L; Li ZG; Liu J; Xie DY; Li WF; Chen C; Zheng B; Chen KN; Dai L; Liao YD; Li K; Li HC; Zhao NQ; Tan LJ
    Ann Oncol; 2023 Feb; 34(2):163-172. PubMed ID: 36400384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
    Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis.
    Qin RQ; Wen YS; Wang WP; Xi KX; Yu XY; Zhang LJ
    Med Oncol; 2016 Apr; 33(4):31. PubMed ID: 26922662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant Chemotherapy and Dose Escalation in Definitive Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma.
    Koh HK; Park Y; Koo T; Park HJ; Lee MY; Chang AR; Hong S; Bae H
    Anticancer Res; 2020 Mar; 40(3):1771-1778. PubMed ID: 32132086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world management and outcomes of older patients with locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study.
    Saito Y; Hamamoto Y; Hirata K; Yamasaki M; Watanabe M; Abe T; Tsubosa Y; Hamai Y; Murakami K; Bamba T; Yoshii T; Tsuda M; Watanabe M; Ueno M; Kitagawa Y
    BMC Cancer; 2023 Mar; 23(1):283. PubMed ID: 36978040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival risk prediction model for patients with pT
    Qi Z; Hu Y; Qiu R; Li J; Li Y; He M; Wang Y
    J Cardiothorac Surg; 2021 May; 16(1):121. PubMed ID: 33933129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
    Hsieh HY; Hsu CP; Yeh HL; Chuang CY; Lin JF; Chang CF
    Kaohsiung J Med Sci; 2018 May; 34(5):281-289. PubMed ID: 29699635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [IMRT-based preoperative neoadjuvant chemoradiotherapy for thoracic esophageal squamous cell carcinoma (ESCC): an analysis of outcome and prognosis].
    Men Y; Hui ZG; Liang J; Feng QF; Chen DF; Zhang HX; Xiao ZF; Zhou ZM; Wang LH
    Zhonghua Zhong Liu Za Zhi; 2016 Sep; 38(9):682-6. PubMed ID: 27647401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Patterns of recurrence in patients with stage pT3N0M0 thoracic esophageal squamous cell carcinoma after two-field esophagectomy].
    Wang Y; Wang L; Yang Q; Li J; He M; Yao J; Qi Z; Li B; Qiao X
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):48-54. PubMed ID: 26796807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postoperative Adjuvant Therapy for Patients with pN+ Esophageal Squamous Cell Carcinoma.
    Li J; Qiu R; Hu Y; Wang Y; Qi Z; He M; Li Y
    Biomed Res Int; 2021; 2021():8571438. PubMed ID: 33553432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymph node volume predicts survival in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy and surgery.
    Pao TH; Chen YY; Chang WL; Wu SY; Lai WW; Tseng YL; Chung TJ; Lin FC
    PLoS One; 2024; 19(3):e0300173. PubMed ID: 38547184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Long-term efficacy and safety of simultaneous integrated boost radiotherapy in non-operative esophageal squamous cell carcinoma: a multicenter retrospective data analysis (3JECROG R-05)].
    Wang XM; Wang L; Wang X; Chen JQ; Li C; Zhang WC; Ge XL; Shen WB; Hu MM; Yuan QQ; Xu YG; Hao CL; Zhou ZG; Qie S; Lu N; Han C; Pang QS; Wang P; Sun XC; Zhang KX; Li GF; Li L; Liu ML; Wang YD; Qiao XY; Zhu SC; Zhou ZM; Zhao YD; Xiao ZF
    Zhonghua Zhong Liu Za Zhi; 2021 Aug; 43(8):889-896. PubMed ID: 34407597
    [No Abstract]   [Full Text] [Related]  

  • 36. Lack of any prognostic value of body mass index for patients undergoing chemoradiotherapy for esophageal squamous cell carcinoma.
    Zhang F; Wang CS; Sun B; Tian GB; Cao FL; Cheng YF
    Asian Pac J Cancer Prev; 2014; 15(7):3075-9. PubMed ID: 24815450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endoscopic resection as an independent predictive factor of local control in patients with T1bN0M0 esophageal squamous cell carcinoma treated with chemoradiotherapy: a retrospective study.
    Miyazaki T; Myojin M; Hosokawa M; Aoyama H; Okahara S; Takahashi H
    Radiat Oncol; 2022 Jan; 17(1):11. PubMed ID: 35057830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant chemoradiotherapy for patients with pathologic node-positive esophageal cancer following radical resection is associated with improved survival.
    Zheng B; Chen M; Chen C; Xiao J; Cai B; Zhang S; Liang M; Zeng T; Chen H; Wu W; Xu G; Zheng W; Zhu Y; Chen C
    Ann Transl Med; 2020 Dec; 8(24):1633. PubMed ID: 33490145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors of radiotherapy in patients with node-positive thoracic esophageal squamous cell carcinoma after radical surgery.
    Lu JC; Tao H; Chen ZZ; Qian PD
    Dis Esophagus; 2009; 22(6):490-5. PubMed ID: 19191849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant radiotherapy for patients with pathologic node-negative esophageal carcinoma: A population based propensity matching analysis.
    Gao HJ; Shang XB; Gong L; Zhang HD; Ren P; Shi GD; Wei YC; Yu ZT
    Thorac Cancer; 2020 Feb; 11(2):243-252. PubMed ID: 31828980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.